[go: up one dir, main page]

AU2001285318A1 - Use of an aldosterone receptor antagonist to improve cognitive function - Google Patents

Use of an aldosterone receptor antagonist to improve cognitive function

Info

Publication number
AU2001285318A1
AU2001285318A1 AU2001285318A AU8531801A AU2001285318A1 AU 2001285318 A1 AU2001285318 A1 AU 2001285318A1 AU 2001285318 A AU2001285318 A AU 2001285318A AU 8531801 A AU8531801 A AU 8531801A AU 2001285318 A1 AU2001285318 A1 AU 2001285318A1
Authority
AU
Australia
Prior art keywords
receptor antagonist
aldosterone receptor
cognitive function
improve cognitive
aldosterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001285318A
Inventor
Kenton N. Fedde
Alfonzo T Perez
Joseph F Tooley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of AU2001285318A1 publication Critical patent/AU2001285318A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Aldosterone receptor antagonists for the prevention and treatment of cognitive dysfunction are disclosed.
AU2001285318A 2000-08-28 2001-08-28 Use of an aldosterone receptor antagonist to improve cognitive function Abandoned AU2001285318A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22873800P 2000-08-28 2000-08-28
US60/228,738 2000-08-28
PCT/US2001/026760 WO2002017895A2 (en) 2000-08-28 2001-08-28 Use of an aldosterone receptor antagonist to improve cognitive function

Publications (1)

Publication Number Publication Date
AU2001285318A1 true AU2001285318A1 (en) 2002-03-13

Family

ID=22858397

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001285318A Abandoned AU2001285318A1 (en) 2000-08-28 2001-08-28 Use of an aldosterone receptor antagonist to improve cognitive function

Country Status (10)

Country Link
US (2) US20020111337A1 (en)
EP (1) EP1313485B1 (en)
JP (1) JP2004507495A (en)
AT (1) ATE306272T1 (en)
AU (1) AU2001285318A1 (en)
CA (1) CA2419256A1 (en)
DE (1) DE60114027T2 (en)
DK (1) DK1313485T3 (en)
ES (1) ES2251505T3 (en)
WO (1) WO2002017895A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005513024A (en) 2001-11-23 2005-05-12 アクゾ・ノベル・エヌ・ベー Treatment of major depressive disorder with glucocorticoid receptor antagonists
PL372055A1 (en) * 2002-04-26 2005-07-11 Schering Aktiengesellschaft Treatment of hypertension in women receiving hormone replacement therapy
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
AU2003278434A1 (en) * 2002-11-05 2004-06-07 Schering Aktiengesellschaft Cardiovascular protection using anti-aldosteronic progestins
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
WO2004041288A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
JPWO2004060400A1 (en) * 2003-01-06 2006-05-11 那波　宏之 Antipsychotic drug targeting epidermal growth factor receptor
US7485094B2 (en) * 2003-09-30 2009-02-03 Smithmarks, Inc. Methods of diagnosis using pulse volume measurement
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US20090265215A1 (en) * 2008-04-22 2009-10-22 Paul Bernhard Lindstrom Methods and apparatus to monitor audience exposure to media using duration-based data
WO2012059594A1 (en) * 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
EP2665707B1 (en) 2011-01-20 2017-01-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
EP2697203B1 (en) 2011-04-13 2017-05-24 Merck Sharp & Dohme Corporation Mineralocorticoid receptor antagonists
EP2765860B1 (en) 2011-10-13 2016-08-17 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
WO2013055608A1 (en) 2011-10-13 2013-04-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
US9505730B2 (en) 2011-10-13 2016-11-29 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
AR091731A1 (en) 2012-07-19 2015-02-25 Merck Sharp & Dohme MINERALOCORTICOID RECEIVER ANTAGONISTS
US10039772B2 (en) * 2015-11-13 2018-08-07 Pietro Paolo Sanna Methods and compositions for treating alcohol use disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133012A (en) * 1961-06-28 1964-05-12 Universal Oil Prod Co Combination catalytic reforming process
US3257390A (en) * 1963-06-12 1966-06-21 Merck & Co Inc Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents
IE51145B1 (en) * 1980-03-07 1986-10-15 Efamol Ltd Pharmaceutical and dietary compositions
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
DE3506100A1 (en) * 1985-02-18 1986-08-21 Schering AG, 1000 Berlin und 4709 Bergkamen 1 (ALPHA) .7 (ALPHA) -DITHIO-SUBSTITUTED SPIROLACTONE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT
FR2634376B1 (en) * 1988-07-21 1992-04-17 Farmalyoc NOVEL SOLID AND POROUS UNIT FORM COMPRISING MICROPARTICLES AND / OR NANOPARTICLES, AS WELL AS ITS PREPARATION
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
ATE225367T1 (en) * 1996-12-11 2002-10-15 Searle & Co METHOD FOR PRODUCING 3-KETO-7ALPHA-ALKOXYCARBONYL-DELTA4.5 STEROIDS AND INTERMEDIATE PRODUCTS
DE19654609A1 (en) * 1996-12-20 1998-06-25 Schering Ag Therapeutic progestogens for the treatment of premenstrual dysphoric disorder
ID29778A (en) * 1998-11-06 2001-10-11 Searle & Co COMBINATION TREATMENT OF ANGIOTENS CHANGES AND ALDOSTERONE ANTAGONISTS TO REDUCE MORBIDITY AND MORTALITY FROM CARDIOVASCULAR DISEASE
UA74141C2 (en) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Oral pharmaceutical compositions comprising micronized eplerenone (variants), method for its production and method for treating aldosterone-mediated states (variants)
CA2364169A1 (en) * 1999-03-05 2000-09-08 G.D. Searle Llc Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease

Also Published As

Publication number Publication date
ATE306272T1 (en) 2005-10-15
ES2251505T3 (en) 2006-05-01
US20020111337A1 (en) 2002-08-15
DE60114027T2 (en) 2006-07-13
US20060058274A1 (en) 2006-03-16
CA2419256A1 (en) 2002-03-07
EP1313485A2 (en) 2003-05-28
DE60114027D1 (en) 2006-02-23
WO2002017895A3 (en) 2003-02-06
JP2004507495A (en) 2004-03-11
EP1313485B1 (en) 2005-10-12
WO2002017895A2 (en) 2002-03-07
DK1313485T3 (en) 2005-12-27

Similar Documents

Publication Publication Date Title
AU2001285318A1 (en) Use of an aldosterone receptor antagonist to improve cognitive function
MXPA04000586A (en) Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor.
AU3652102A (en) Compounds and their uses
YU20600A (en) This invention relates to the use of 5-ht3 receptor
UA87473C2 (en) Muscarinic acetycholine receptor antagonists
WO2003029262A3 (en) The human mob-5 (il-24) receptors and uses thereof
MXPA04008772A (en) Naltrexone hydrochloride compositions.
IL155703A0 (en) Treatment of sexual dysfunction with non peptide bombesin receptor antagonists
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
SG188700A1 (en) Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
SG149872A1 (en) Antagonists of the bradykinin b1 receptor
MXPA06000662A (en) Muscarinic acetylcholine receptor antagonists.
TW200519109A (en) Muscarinic acetylcholine receptor antagonists
MXPA06000663A (en) Muscarinic acetylcholine receptor antagonists.
MY137620A (en) Therapeutic treatment
WO2002011732A8 (en) Novel bicyclic and tricyclic pyrrolidine derivatives as gnrh antagonists
IL132853A0 (en) Combination therapy for modulating the human sexual response
AU2001216580A1 (en) Use of an epoxy-steroidal aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects
EP1246619A4 (en) Urotensin-ii receptor antagonists
CA2416879A1 (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
AU6503900A (en) Chemokine receptor antagonists and methods of use therefor
AU6389900A (en) Chemokine receptor antagonists and methods of use therefor
AU2002302735A1 (en) 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists
WO2004112729A3 (en) Dual function compounds and uses thereof
ZA200403530B (en) Chemokine receptor antagonists and methods of use thereof.